Alfonso Quintas Cardama
Chief Medical OfficerDr. Alfonso Quintás Cardama, M.D., serves as Chief Medical Officer of Foghorn Therapeutics Inc. since September 11, 2023. He joined TCR2 Therapeutics Inc. (formerly known as TCR2, Inc.). in 2017 and served as its Chief Medical Officer since 2017. Dr. Quintás Cardama was the Clinical Development Head of the Cell & Gene Therapies Unit at GlaxoSmithKline PLC in 2017. Between 2014 and 2016, he served as Global Clinical Leader, Cell & Gene Therapy, at Novartis AG and was an Assistant Professor in the Department of Leukemia at The University of Texas, MD Anderson Cancer Center from 2009 to 2014. Dr. Quintás Cardama received his M.D. from the Universidad de Santiago de Compostela School of Medicine in Spain. He completed an internship and residency in the Department of Medicine of the Albert Einstein College of Medicine—Yeshiva University and a hematology and oncology fellowship and a leukemia fellowship at The University of Texas, MD Anderson Cancer Center.
Positions
- Company NameFoghorn Therapeutics Inc.Stock CodeFHTXPositionChief Medical OfficerColleagues
